CBD, CBG and CBN: comparing their differences and research

6 hours ago

5 min read

Short answer: CBD, CBG and CBN are three different cannabinoid compounds: cannabidiol, cannabigerol and cannabinol. They are not three strengths of the same substance. Their differences concern chemical structure and the available scientific evidence. Neither an abbreviation nor a percentage tells you which substance would be better suited to a particular person.

This comparison separates three questions: which substance is meant? What has actually been studied? Which details describe a specific product? Our detailed individual profiles provide further information about CBD, CBG and CBN.

CBD, CBG and CBN: names and chemical differences

Abbreviation	Compound name	Molecular formula
CBD	Cannabidiol	C₂₁H₃₀O₂
CBG	Cannabigerol	C₂₁H₃₂O₂
CBN	Cannabinol	C₂₁H₂₆O₂

Molecular formulas identify the types and numbers of atoms in a molecule. They are chemical identifiers, not assessments of effectiveness. These different formulas already make one point clear: CBG and CBN are not simply other names for CBD. The chemical information is documented in the NIST publication on cannabinoid analysis, Table 1.

Similar-sounding abbreviations should also be kept separate: CBDA and CBGA refer to the acidic forms, cannabidiolic acid and cannabigerolic acid; they are distinct from CBD and CBG. CBN, by contrast, can form as a product of THC oxidation. This describes a chemical relationship; it does not mean that every CBN product contains THC or is THC-free. Its actual composition remains decisive.

Compound name, spectrum and oil describe different things

‘CBG’ names a compound. ‘CBG oil’ describes a product whose other components can only be established from its ingredients and product information. Similarly, CBD and CBD oil, or CBN and CBN oil, are not interchangeable terms.

Terms such as full spectrum and broad spectrum add another layer. They do not replace either the names of the declared cannabinoids or their quantities. When comparing two products, consider the compound, composition and fill volume separately. Our article on hemp oil, hemp seed oil and CBD oil explains the distinction between plant extract and carrier oil.

How does the research differ?

A responsible comparison does not simply count studies or positive headlines. What matters is whether a study involved people or experimental models, which preparation was used and which specific question the study was designed to answer.

CBD: medicinal evidence applies to specific preparations and conditions

Epidyolex is an EU-authorised medicinal product containing cannabidiol for certain rare forms of epilepsy. The European Medicines Agency describes this medicine’s indications, benefits and risks. This neither grants general authorisation to CBD oils nor demonstrates that an arbitrary shop product is effective. The evidence relates to a particular preparation and indication.

CBG: an example of early human research

Cuttler and colleagues (2024) studied 34 healthy adults with cannabis experience in a double-blind, placebo-controlled crossover trial. One subjective anxiety rating showed more favourable changes with the CBG preparation. Not all anxiety and stress measures used confirmed a difference. The study was small, assessed short-term effects and did not adjust for the number of statistical comparisons. This is an avenue of research, not evidence for treating an anxiety disorder. The preparation also contained other components; the study did not test a Parmorcan® product.

CBN: sleep measurements do not support a blanket promise of better sleep

Lavender and colleagues (2026) studied 20 people with diagnosed insomnia in a randomised, placebo-controlled crossover trial. For the primary outcome, wake after sleep onset, the difference from placebo was not statistically established. Some other sleep measures were more favourable. Individual treatment nights were studied; the small sample and short duration limit the conclusions. The work does not establish a reliable everyday treatment and did not test a Parmorcan® product either.

Why this does not produce a ranking of CBD, CBG and CBN

These studies do not compare all three substances under the same conditions. A finding on a subjective anxiety rating cannot be weighed directly against an objective sleep measurement. Similarly, a medicinal assessment for a particular form of epilepsy is not a quality score for every product bearing the same compound name.

A reliable ranking for a specific question would require suitable head-to-head studies with appropriate populations, comparable preparations and predefined outcomes. Our guide to reading cannabinoid studies provides more background. Claims that a combination is inherently superior also need their own evidence; the entourage effect is not a general substitute for it.

Percentages cannot be compared as measures of effect

‘10% CBG’ refers to a different compound from ‘10% CBN’. The same numerical value therefore means neither the same biological effect nor the same research evidence. Comparing ‘20% CBD’ with ‘10% CBN’ does not justify saying ‘twice as effective’ either.

It must also be clear what a percentage is measured against. Bottle contents in millilitres are a separate measure of volume. Our guide to units in laboratory reports explains mass per mass, mass per volume and percentages. These figures describe a product; they do not establish a health benefit.

A checklist for an objective product comparison

Identify the compounds clearly: which cannabinoids are declared? Are CBD, CBG and CBN listed separately?
Read the composition: which carrier oil and other ingredients are listed? A set containing several bottles is not a single combined formulation.
Compare quantities separately: fill volume, concentration and price describe different properties. A higher percentage alone is not a quality score.
Match the evidence: do the product or sample name and full batch identifier match the linked report? The laboratory reports overview lists the report date and report number.
Respect the limits of a finding: detecting a cannabinoid is not clinical evidence of effectiveness. A report does not automatically confirm properties that were not tested.

Safety: a different compound does not mean no risk

The EMA describes risks of the CBD medicine that include sleepiness and possible liver problems. Frequencies observed during this medicinal treatment cannot simply be transferred to other products. They do show why ‘plant-based’ is not an adequate safety assessment.

The CBG and CBN studies discussed here cannot comprehensively establish rare risks or long-term consequences. Less evidence does not mean greater safety. If you take medicines or have medical questions, an individual assessment by a doctor or pharmacist is appropriate. Our article on cannabinoids and medicines explains the background.

Conclusion: keep three levels distinct

CBD, CBG and CBN are chemically distinct. Their research evidence must be assessed for the question being asked. A particular oil or distillate, in turn, is described by its complete product information and evidence that can be matched to it. Separating these three levels makes the differences easier to understand without turning an abbreviation or percentage into an unsupported promise of effects.

Scientific editor: Dipl.-Chem. Mohammad Reza Talebnasab, owner of Parmorcan®. Sources reviewed: 21 October 2026. This article provides general scientific information. It does not replace diagnosis or individual medical advice and contains no recommendation for using a product.